← Neurocrine Biosciences
What podcasts say about Neurocrine Biosciences
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Neurocrine Biosciences
3 statements · 3 positive
Any cash flow from Neurocrine’s Vykat deal could benefit its stock.
“are they going to generate any sort of cashflow from the deal would, would maybe be a positive for the stock.”
Open the episode · Episode 202 - November 6, 2026Listen at 35:17
Cramer approves Neurocrine because it is profitable.
“Because it's profitable, I'm going to say fine.”
Open the episode · Mad Money w/ Jim Cramer 8/17/26Listen at 35:49
Cramer evaluates Neurocrine Biosciences as performing well.
“But I will say NeuroCream does a good job.”
Open the episode · Mad Money w/ Jim Cramer 8/17/26Listen at 36:01
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.